Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Golnerminogene pradenovec

Drug Profile

Golnerminogene pradenovec

Alternative Names: ADgvEGR.TNF.11D; TNF-α gene therapy - GenVec; TNFerade; Tumour necrosis factor-alpha gene therapy - GenVec

Latest Information Update: 29 Jun 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Asahi Kasei
  • Developer GenVec; National Cancer Institute (USA)
  • Class Antineoplastics; Cytokine genes; Gene therapies
  • Mechanism of Action Gene transference; Tumour necrosis factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Head and neck cancer; Malignant melanoma; Oesophageal cancer; Pancreatic cancer; Prostate cancer; Sarcoma

Most Recent Events

  • 16 Jun 2017 GenVec was acquired by Intrexon Corporation
  • 04 Sep 2013 Golnerminogene pradenovec is available for licensing as of 04 Sep 2013. http://www.genvec.com/
  • 02 Nov 2010 GenVec receives Qualifying Therapeutic Discovery Project grant from the US Government for Golnerminogene pradenovec development in Cancer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top